Trial
NCT01381926
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Alabama at Birmingham
Collaborators
Amylin Pharmaceuticals, LLC.
Condition
Type 2 Diabetes Mellitus
Intervention
exenatide
Why stopped
unavailability of study drug and matching placebo
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-14